mRNA Therapy Rejuvenates Aging Immune Systems in Mice, Boosting Vaccine and Cancer Treatment Response

A groundbreaking mRNA therapy has successfully rejuvenated the aging immune systems of mice, offering new hope for addressing the weakened immunity that comes with age. The treatment, delivered twice weekly as a cocktail of three messenger RNAs, restored T cell function and boosted responses to both vaccinations and cancer treatments, according to research published in Nature on December 17.

The study, led by Mirco Friedrich, a hematologist and oncologist at the German Cancer Research Center in Heidelberg, addresses a fundamental challenge of aging: the gradual decline of immune function that makes older adults more vulnerable to infections and less responsive to medical interventions.

Targeting Age-Related Immune Decline

As people age, their ability to produce T cells—immune cells that coordinate responses and kill infected cells—significantly diminishes. The root cause lies in the thymus gland, a small organ above the heart responsible for T cell maturation. "The thymus degrades with age: it begins to shrink and is gradually replaced by fatty tissue," Friedrich explained.

This thymic involution has far-reaching consequences. T-cell aging helps explain why vaccines are sometimes less effective in older people than in young adults, and why cancer treatments that unleash the immune system against tumors don't work as well in older adults, according to María Mittelbrunn, an immunologist at the Spanish National Research Council in Madrid who was not involved in the study.

"T cells, in particular, are one of the cell types that change the most during aging," Mittelbrunn noted. "To rejuvenate them could have immense consequences."

Novel Liver-Targeted Approach

Previous attempts to reverse thymic decline using hormone treatments or other drugs have failed, prompting Friedrich and his colleagues to pursue a different strategy. Rather than directly treating the thymus, they targeted T cells by delivering experimental therapy to the liver.

"Most T cells are in the blood," Friedrich explained. "And the liver receives the body's whole blood volume."

The researchers identified three particular signals crucial for immune cell function that weaken as the thymus shrinks. Using mRNA molecules packaged in tiny fat droplets, they found a way to artificially substitute these missing signals by introducing them to liver cells in mice.

Promising Results and Safety Design

The treatment enabled older mice to produce more T cells and ward off illness more effectively. The animals showed improved responses to vaccinations and enhanced ability to fight tumors, demonstrating the therapy's potential across multiple immune challenges.

Importantly, the researchers deliberately designed the mRNA therapy to be temporary. The mRNA converts into proteins in the liver for only a short time, and the signaling factors produced disappear after a while. This approach allows for precise dosing control and minimizes the risk of unintended long-term changes.

"The immune system ages but it does not irreversibly lose its abilities," Friedrich said. "If we provide it with the missing signals again, it can once more perform amazing feats."

Broader Implications for mRNA Technology

The study highlights the expanding potential of mRNA technology beyond its well-known applications in vaccines such as those used to tackle COVID-19. The liver-targeted approach takes advantage of the organ's natural function of releasing large amounts of proteins into the bloodstream, making it an ideal delivery system for systemic immune enhancement.

The research team, which included scientists from the German Cancer Research Centre, the Hi-Stem institute, and the Broad Institute, presented their findings at the American Society of Hematology annual meeting in Orlando, Florida, earlier this month before the Nature publication.

The breakthrough represents a significant step toward addressing the clinical challenges posed by immunosenescence—the age-related decline in immune function that contributes to increased susceptibility to infections, reduced vaccine efficacy, and poor responses to cancer immunotherapies in older populations.